Giredestrant Delivers Long-Sought Adjuvant Benefit

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Adjuvant endocrine therapy is standard for hormone receptor-positive breast cancer.
• Existing therapies include tamoxifen, letrozole, anastrozole, and exemestane.
• There has been limited progress in adjuvant endocrine therapy options for two decades.

Purpose of the Study:

• To evaluate the efficacy of giredestrant compared to standard endocrine therapies in the adjuvant setting.
• To assess the impact of giredestrant on invasive disease-free survival.

Main Methods:

• Phase III randomized controlled trial (lidERA study).
• Comparison of oral selective estrogen receptor degrader (giredestrant) versus standard endocrine therapies.
• Primary endpoint: invasive disease-free survival.

Main Results:

• Giredestrant demonstrated prolonged invasive disease-free survival compared to standard endocrine therapies.
• The study represents the first improvement in adjuvant endocrine therapy in 20 years.

Conclusions:

• Giredestrant shows promise as an effective adjuvant endocrine therapy for breast cancer.
• Further research is needed to compare giredestrant with CDK4/6 inhibitors and assess cost-effectiveness.